BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cambrex Corporation (CBM) Announces Appointment of Shlomo Yanai as Vice Chairman of the Board of Directors


11/29/2012 9:58:38 AM

EAST RUTHERFORD, N.J., Nov. 29, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) announced that Shlomo Yanai was appointed to its Board of Directors yesterday and will serve as its Non-Executive Vice Chairman. Mr. Yanai, who retired in mid-2012 as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., the largest generic pharmaceutical manufacturer in the world, has extensive experience in the life sciences industry. As Vice Chairman of the Cambrex Board, he will work closely with the Company's other directors and its leadership team to formulate and help execute Cambrex's growth strategies.

"We are excited to have Mr. Yanai join Cambrex's Board of Directors," said Chairman John Miller. "Shlomo's exceptional career at Teva positions him well to make significant contributions to the success of our Company. His in-depth knowledge of our industry will enhance our ability to build on the progress we've made and will provide us with valuable insight as we seek and evaluate growth opportunities."

Cambrex's President and Chief Executive Officer Steven M. Klosk commented, "Shlomo's outstanding background in the pharmaceutical industry will be a great asset to us as we continue to implement our strategic initiatives to grow sales of active pharmaceutical ingredients and finished dosage form products for the branded and generic markets."

Mr. Yanai served from 2007 until mid-2012 as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., during which time Teva increased revenues from $8.4 billion to approximately $20 billion. From 2003 to 2006, Mr. Yanai was the President and Chief Executive Officer of Makhteshim Agan Industries, a leading global agro-chemicals company. Mr. Yanai also served as a member of the Board of Directors of the Bank Leumi Le-Israel, Israel's second largest bank, LycoRed Natural Products Industries and I.T.L. Optronics Ltd. Until his retirement from the Israeli Army in 2001 at the rank of Major General, Mr. Yanai was the head of the Strategy Planning Branch of General Headquarters of the Israel Defense Forces. Currently, Mr. Yanai is a member of the Board of Governors of Technion, the Israel Institute of Technology and the International Advisory Board, M.B.A. program of Ben-Gurion University. He is also an honorary member of the Board of The Institute for Policy and Strategy of the Interdisciplinary Center (IDC), Herzliya.

"The Cambrex team has been very successful in propelling the worldwide growth of the Company and I am looking forward to contributing to the Company's initiatives to continue this success," commented Mr. Yanai.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.

SOURCE Cambrex Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES